Natalie Byrne

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas et al. · Cancer Research · 2010 · 264 citations · Full text

Medicine, Oncology, Pharmacology +17

Transmission of <i>Cryptosporidium</i> Species Among Human and Animal Local Contact Networks in Sub-Saharan Africa: A Multicountry Study

Ralf Krumkamp, Cassandra Aldrich, Oumou Maïga‐Ascofaré et al. · Clinical Infectious Diseases · 2020 · 54 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · Journal of Clinical Oncology · 2020 · 48 citations

Medicine, Oncology, Pharmacology +15